NOV. 21. 2005 12:44PM PABST PATENT GROUP NO. 6116 P. 15

U.S.S.N. 10/003.983 Filed: October 31, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

Remarks

Election/Restriction

Applicants have petitioned the Group Director to review the restriction requirement set forth in the Office Action mailed on October 4, 2004, as maintained in the Office Action mailed May 23, 2005. The petition was sent via facsimile on October 17, 2005.

Rejection Under 35 U.S.C. § 112, first paragraph, enablement

Claims 1-4, 6 and 7 were rejected under 35 U.S.C. § 112, first paragraph, as not being enabled, for sequences other than those present in the contiguous sequence of human CD45. Applicants respectfully traverse this rejection to the extent that it is applied to the claims as amended. Claims 1 and 7 have been canceled to facilitate prosecution. Therefore, all rejections of claims 1 and 7 are now moot. The remaining claims have been amended to limit the claims to a single peptide or a variant thereof. This amendment is not to be construed as an admission that the claims are not enabled or patentable for their full scope. Claim 42 has been added to define the peptide as FLYDVIAST (SEQ ID NO:1). Support for new claim 42 can be found in the specification at least at page 5, lines 10-11.

Claim 2 has been amended into independent format to define a peptide containing 9 to 12 amino acid residues, wherein the peptide contains an HLA-binding peptide of the human CD45 polypeptide containing the amino acid sequence FLYDVIAST (SEQ ID NO:1) or a variant of SEQ ID NO:1, wherein the variant contains one or two amino acid substitutions at position 2 and/or position 9. Support for this amendment can be found in the specification at least at page 7, line 21, page 3, lines 24-25, page 4, lines 26-27 and page 6, lines 17-20 and line 28. Claim 2, ICI 103

11 078230/00030

AMENDMENT AND RESPONSE TO OFFICE ACTION

as amended, is enabled by the specification. The amino acid sequence of CD45 is disclosed in the specification at least at page 4, lines 22-24. Peptides of CD45 are disclosed in the specification at least at page 3, lines 24-26, page 4, lines 15-20 and page 5, lines 6-8. The preferred lengths of peptides are disclosed in the specification at least at page 8, lines 24-25. Methods for generating peptides are disclosed in the specification at least at the paragraph spanning page 9 and 10. Variants of peptides and methods for producing variants are disclosed in the paragraph spanning page 6 and 7. Peptides capable of binding to HLA-A0201, as defined by claim 3, are disclosed in the specification at least at Example 1. Peptide-bound HLA-A0201 capable of eliciting the production of a cytotoxic T lymphocyte (CTL), as defined in claim 4, is disclosed in the specification at least at page 8, lines 16-22, page 16, lines 25-28, page 17, lines 1-4. Methods for producing such CTL are disclosed in the specification at least at the paragraph spanning page 17 and 18, and at pages 18-21. It is clear from the guidance provided in the specification that it would not require undue experimentation to generate the peptides as defined by claims 2-4, 6 and 42, as amended.

Rejection Under 35 U.S.C. § 112, first paragraph, written description

Claims 1-4, 6 and 7 were rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventor had possession of the claimed invention. Applicants respectfully traverse this rejection to the extent that it is applied to the claims as amended.

12 ICI 103 4506114601 078230/00030

AMENDMENT AND RESPONSE TO OFFICE ACTION

The Examiner has rejected the claims for lack of written description because allegedly the claims encompass amino acid sequences not present in the contiguous sequence of human CD45. Claim 2, as amended, defines a peptide containing 9 to 12 amino acid residues, wherein the peptide contains an HLA-binding peptide of the human CD45 polypeptide containing the amino acid sequence FLYDVIAST (SEQ ID NO:1) or a variant of SEQ ID NO:1, wherein the variant contains one or two amino acid substitutions at position 2 and/or position 9. As discussed above, the amino acid sequence of CD45 is disclosed in the specification at least at page 4, lines 22-24. Peptides of CD45 are disclosed in the specification at least at page 3, lines 24-26, page 4, lines 15-20 and page 5, lines 6-8. The preferred lengths of peptides are disclosed in the specification at least at page 8, lines 24-25. Methods for generating peptides are disclosed in the specification at least at the paragraph spanning page 9 and 10. Variants of peptides and methods for producing variants are disclosed in the paragraph spanning page 6 and 7. Therefore, the claims, as amended, are described in such a way as to reasonably convey to one skilled in the art that the inventor had possession of the peptide as defined by the claims of the present application.

Rejection Under 35 U.S.C. § 112, second paragraph

Claims 1, 4 and 7 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite. Applicants respectfully traverse this rejection to the extent that it is applied to the claims as amended.

The Examiner has rejected claim 4 for allegedly being indefinite for recitation of the phrase "a polypeptide expressing the given amino acid sequence." Claim 4, as amended, recites

13

1CI 103
07823000030

AMENDMENT AND RESPONSE TO OFFICE ACTION

"a polypeptide comprising the HLA-binding peptide of human CD45 polypeptide." Support for this amendment can be found in the specification at least at page 16, lines 25-27 and page 22, lines 6-9. Claim 4, as amended, is definite.

Rejection Under 35 U.S.C. § 102

Claims 1-3 and 6 were rejected under 35 U.S.C. § 102(b) as being anticipated by (1) UniProt Accession No. Q29311 (1996) ("Q29311") as evidenced by The Leukocyte Antigen Fact Book 2nd ed., pp. 244-247, Academic Press (1997) ("Leukocyte") and alleged admissions in the specification at Example 1 and Figure 1; (2) International Application WO 92/13887 by Humphries ("Humphries") as evidenced by Leukocyte and alleged admissions in the specification at Example 1 and Figure 1; and (3) UniProt Accession No. P06800 (1988) ("P06800") as evidenced by Leukocyte and alleged admissions in the specification at Example 1 and Figure 1. Claims 1-3 and 6 were rejected under 35 U.S.C. § 102(e) as being anticipated by U. S. Patent No. 6,060,054 to Staerz ("Staerz") as evidenced by Leukocyte and alleged admissions in the specification at Example 1 and Figure 1. Claims 1-3 and 6 were rejected under 35 U.S.C. § 102(a) as being anticipated by Staerz as evidenced by Leukocyte and alleged admissions in the specification at Example 1 and Figure 1. Applicants respectfully traverse these rejections to the extent that it is applied to the claims as amended. Claim 1 has been canceled. Therefore, all rejections of claim 1 are now moot.

None of the references cited by the Examiner anticipate the claims of the present application.

14 ICI 103 45061146vI 078230/00030 NOV. 21. 2005 12:46PM PABST PATENT GROUP NO. 6116 P. 19

U.S.S.N. 10/003,983 Filed: October 31, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

The Legal Standard

For a rejection of claims to be properly founded under 35 U.S.C. § 102, it must be

established that a prior art reference discloses each and every element of the claims. Hybritech

Inc v Monoclonal Antibodies Inc, 231 USPQ 81 (Fed. Cir. 1986), cert. denied, 480 US 947

(1987); Scripps Clinic & Research Found v Genentech Inc, 18 USPQ2d 1001 (Fed. Cir. 1991).

The Federal Circuit held in Scripps, 18 USPQ2d at 1010:

Invalidity for anticipation requires that all of the elements and limitations of the

claim are found within a single prior art reference. There must be no difference

between the claimed invention and the reference disclosure, as viewed by a person of

ordinary skill in the field of the invention. (Emphasis added)

A reference that fails to disclose even one limitation will not be found to anticipate, even

if the missing limitation could be discoverable through further experimentation. As the Federal

Circuit held in Scripps, Id.:

[A] finding of anticipation requires that all aspects of the claimed invention were already

described in a single reference: a finding that is not supportable if it is necessary to prove

facts beyond those disclosed in the reference in order to meet the claim limitations. The

role of extrinsic evidence is to educate the decision-maker to what the reference meant to

persons of ordinary skill in the field of the invention, not to fill in the gaps in the

reference.

For a prior art reference to anticipate a claim, it must enable a person skilled in the art to

make and use the invention. "A claimed invention cannot be anticipated by a prior art reference

45061146√1

15

ICI 103 078230/00030

AMENDMENT AND RESPONSE TO OFFICE ACTION

if the allegedly anticipatory disclosures cited as prior art are not enabled". Amgen, Inc. v.

Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1354, 65 USPQ2d 1385, 1416 (Fed. Cir. 2003).

The References cited by the Examiner do not anticipate each and every element of the claims.

The Prior Art

Q29311

Q29311 discloses a 74 amino acid fragment of porcine leukocyte common antigen (CD45).

Leukocyte

Leukocyte discloses the amino acid sequence of human CD45.

Humphries

Humphries discloses peptides for regulating or controlling cell adhesion. Humphries discloses that a fragment of CD45 can bind to MOLT-4 cells (human lymphoblastic leukemia cells) and that a fragment of CD45 can cause cell spreading of A375-SM cells (human metastatic melanoma cells).

P06800

P06800 discloses a portion of murine CD45.

Staerz

Staerz discloses products and processes for suppressing an immune response using a Tlymphocyte immunosuppression molecule. Staerz discloses CD45, having 553 amino acids.

The Examiner does not cite a single prior art reference that discloses each and every element of the claims. As noted above, a claim is anticipated only if each and every element as

AMENDMENT AND RESPONSE TO OFFICE ACTION

set forth in the claim is found, either expressly or inherently described, in a single prior art reference." Verdegaal Bros. v. Union Oil Co. of California, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987). The Examiner has rejected the claims over combinations of references and in conjunction with the disclosure of the present application, which is not permissible. Therefore, the claims are not anticipated because the claims are not described in a single prior art reference.

In addition, none of the cited references, alone or in combination, disclose or suggest a peptide of 9 to 12 amino acid residues, wherein the peptide contains an HLA-binding peptide present in the 533 amino acid sequence of human CD45. None of the references, alone or in combination, disclose or suggest a peptide of 9 to 12 amino acid residues containing the amino acid sequence FLYDVIAST (SEQ ID NO:1) or a variant of SEQ ID NO:1. None of the cited references disclose or suggest which peptides present in the 533 amino acid sequence of human CD45 bind HLA molecules. Therefore, the cited references do not disclose or suggest each and every element of the claims. Therefore, claims 2, 3 and 6 are not anticipated by Q29311, Leukocyte, Humphries, P06800 and Staerz.

Rejection Under 35 U.S.C. § 103

Claims 1-4 and 6 were rejected under 35 U.S.C. § 103(a) as obvious over (1) International Application WO 97/26328 by RPMS Technology Limited ("WO 97/26328"), in combination with Leukocyte and Rammensee, et al., MHC Ligands and Peptide Motifs, pp 217-227 and 236-281, LANDES Bioscience (1997) ("Rammensee") and (2) WO 97/26328 in combination with Leukocyte and U.S. Patent No. 6,602,510 to Fikes, et al., ("Fikes"). Claim 7 17 ICI 103 45061146v1 078230/00030

AMENDMENT AND RESPONSE TO OFFICE ACTION

was rejected under 35 U.S.C. § 103(a) as obvious over (1) WO 97/26328 in combination with Leukocyte and Rammensee and further in combination with Mottez, et al., J. Exp. Med. 181:493-502 (1995) ("Mottez") and (2) WO 97/26328 in combination with Leukocyte and Fikes and further in combination with Mottez. Applicants respectfully traverse this rejection to the extent that it is applied to the claims as amended.

The Legal Standard

The U.S. Patent and Trademark Office has the burden under 35 U.S.C. § 103 to establish a prima facie case of obviousness. In re Warner et al., 379 F.2d 1011, 154 U.S.P.Q. 173, 177 (C.C.P.A. 1967); In re Fine, 837 F.2d 1071, 1074, 5 U.S.P.Q.2d 1596, 1598-99 (Fed. Cir. 1988). To establish a prima facie case of obviousness, three basic criteria must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings. Second, there must be a reasonable expectation of success. Finally, the prior art reference (or references when combined) must teach or suggest all the claim limitations. The teaching or suggestion to make the claimed combination and the reasonable expectation of success must both be found in the prior art and not based on applicant's disclosure. In re Vaeck, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991).

The prior art must provide one of ordinary skill in the art with the motivation to make the proposed modifications needed to arrive at the claimed invention. In re Geiger, 815 F.2d 686, 2 U.S.P.Q.2d 1276 (Fed. Cir. 1987); In re Lalu and Foulletier, 747 F.2d 703, 705, 223 U.S.P.Q. 1257, 1258 (Fed. Cir. 1984). Claims for an invention are not prima facie obvious if the primary 18 45061146v1

NOV. 21. 2005 12:48PM PABST PATENT GROUP NO. 6116 P. 23

U.S.S.N. 10/003,983

Filed: October 31, 2001.

AMENDMENT AND RESPONSE TO OFFICE ACTION

references do not suggest all elements of the claimed invention and the prior art does not suggest the modifications that would bring the primary references into conformity with the application claims. *In re Fritch*, 23 U.S.P.Q.2d, 1780 (Fed. Cir. 1992); *In re Laskowski*, 871 F.2d 115 (Fed. Cir. 1989). This is not possible when the claimed invention achieves more than what any or all of the prior art references allegedly suggest, expressly or by reasonable implication.

It is clear that to establish a rejection under 35 U.S.C. § 103 the cited references must (1) recite each element of the claims, (2) provide one of skill in the art with the motivation to combine the cited references as applicants have done and (3) provide one of ordinary skill in the art with a reasonable expectation of success. The references cited by the Examiner clearly do not meet all three criteria.

The Prior Art

WO 97/26328

WO 97/26328 discloses a method for generating cytotoxic T lymphocytes (CTL) against selected peptides presented by a patient's HLA class I molecules. WO 97/26328 states that the peptides must be presented abnormally or must be elevated in diseased cells.

45061146v1 19 ICI 103 078230/00030

AMENDMENT AND RESPONSE TO OFFICE ACTION

Rammensee

Rammensee discloses residue motifs for peptides that bind to individual class I HLA molecules.

Leukocyte

Leukocyte discloses the amino acid sequence of human CD45.

Fikes

Fikes discloses peptide epitopes that can be used to monitor an immune response to a tumor associated antigen or to create a cancer vaccine.

(1) The cited references must recite each and every element of the claims.

None of these references, alone or in combination, disclose or suggest a peptide of 9 to 12 amino acid residues, wherein the peptide contains the amino acid sequence FLYDVIAST (SEQ ID NO:1) or a variant of SEQ ID NO:1. Therefore, the claims of the present application are not obvious in view of the cited references.

(2) Provide one of skill in the art with the motivation to combine the cited references as applicants have done.

None of these references provide one of ordinary skill in the art with the motivation to combine these references. None of the references suggest deriving peptides of CD45. WO 97/26328 discloses at pages 7-8 a large list of disease-associated proteins that are suitable targets for tumor immunotherapy. This list does not include CD45. Leukocyte does not disclose or suggest generating peptides of CD45 for immunotherapy. Therefore, one of ordinary skill in that art would not be motivated to combine WO 97/26328 and Leukocyte to identify epitopes of

U.S.S.N. 10/003,983 Filed: October 31, 2001 AMENDMENT AND RESPONSE TO OFFICE ACTION

CD45 for immunotherapy. Furthermore, one of ordinary skill in the art would not be motivated to use CD45 as disclosed in Leukocyte in the method disclosed in WO 97/26328 because CD45 is expressed in haematopoietic malignancies at similar levels as normal cells (see at least page 2, lines 18-19 of the present application) and WO 97/26328 discloses that the antigen for the CTL is expressed abnormally. Since one of ordinary skill in the art would not combine WO 97/26328 and Leukocyte, they would not combine these references further with Rammensee or Fikes. Therefore, the claims are not obvious over the cited references.

(3) Provide one of ordinary skill in the art with a reasonable expectation of success The cited references clearly do not provide one of ordinary skill in the art with a reasonable expectation of success. In addition, the Examiner has not established a prima facie case of obviousness, because the Examiner has not cited a single place in WO 07/26328, Leukocyte, Rammensee, or Fikes that provides one of ordinary skill in the art with a reasonable expectation of success.

As discussed above, one of ordinary skill in the art would not expect the CD45 of Leukocyte to work in the method of WO 97/26328 because as described in the present application CD45 is expressed in haematopoietic malignancies at similar levels as normal cells. Rammensee discusses principles that were allegedly useful to predict peptides that bind MHC molecules. However, binding predictions do not always predict actual binding affinity. There is no way of knowing based on Rammensee whether any CD45 peptides generated through their method would actually bind an HLA molecule. The principles disclosed in Rammensee are provided on the internet at

21 45061146v3

ICI 103 078230/00030

AMENDMENT AND RESPONSE TO OFFICE ACTION

http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm. Applicants inserted the human sequence of CD45 into the program and searched for peptides of 10 residues in length that bind HLA-0201. The results, a copy of which is enclosed, is a list of hundreds of peptides. There is no guidance as to which peptides would actually bind MHC molecules. Without additional guidance, one of skill in the art would have to test each of the peptides to determine which peptides actually bind MHC molecules. In contrast to the unknown properties of Rammensee, Applicants have demonstrated the binding affinity of CD45 peptides (see at least Figure 1 and Example 1).

Rammensee does not provide a reasonable expectation of success for peptides with binding affinity that are also immunogenic (i.e., able to stimulate a CTL response). Based on Rammensee there is no way of knowing whether any of the peptides predicted by Rammensee actually bind the HLA molecule and can stimulate a CTL response. Again in contrast to the cited references, the Applicants have demonstrated immunogenicity of CD45 peptides using allogeneic CTL (see at least Figure 2 and Example 2). This was not predicted but determined experimentally. The cited references also do not provide a reasonable expectation of success for peptides that stimulate CTL to kill tumor cells expressing CD45. Based on the cited references there is no way of knowing which peptides bind the HLA molecule and which actually stimulate a CTL response that would be effective in killing tumor cells that express CD45. Yet again, in contrast to the lack of guidance provided in the cited references, the Applicants have demonstrated that isolated CTLs stimulated by CD45 peptides can kill CD45 expressing tumor cells (see at least Figures 4 and 5). With respect to Fikes, Fikes discloses epitopes of a target 22

45061146~1

AMENDMENT AND RESPONSE TO OFFICE ACTION

antigen that is **not** CD45 that have been identified and validated. Fikes does not disclose or suggest predicting epitopes from other polypeptides. However, even if a skilled person was able to derive a method for predicting peptides from Fikes, Fikes does not provide a reasonable expectation of success regarding which peptides of CD45 have actual binding affinity or which peptides would be effective in stimulating CTLs and kill tumor cells expressing CD45. Therefore, the cited references do not provide one of ordinary skill in the art with a reasonable expectation of success for peptides of CD45. From the forgoing discussion, it is clear that the claims, as amended, are not obvious over the cited art.

Allowance of claims 2-6, and 8-42 is respectfully solicited.


Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Date: November <u>2</u>, 2005


PABST PATENT GROUP LLP 400 Colony Square, Suite 1200 1201 Peachtree Street Atlanta, Georgia 30361 (404) 879-2151 (404) 879-2160 (Facsimile)

23




Epitope prediction

This page allows you to find out the ligation strength to a defined HLA type for a sequence of aminoacids. The algorithmus used are based on the book "MHC Ligands and Peptide Motifs" by H.G.Rammensee, J.Bachmann and S.Stevanovic. The probability of being processed and presented is given in order to predict T-cell epitopes.



1. Select MHC type

l all H2-Ak H2-Db H2-Ek 灛 H2-Kb



decamers (10 aa)

15 - mers (15 aa) for MHC Type II only all mers

Hold down ctrl key when dicking to select multiple items

3. Paste your sequence here:

mylwlkllaf gfafldtevf vtggsptpsp tglttakmps vplssdplpt httafspast ferendfset ttslspdnts tqvspdsldn asafnttgvs svqtphlpth adsqtpsagt You may use SYFPEITHI with H2-K6 to see an example

4. Choose Run to start analysis



Run Reset

Home

go to top

22

22

22

22

22

22

22

Search Report

Return to search conditions
HLA-A*0201 decamers



HLA-A*0201 decamers

Pos

	1	2	3	4	5	6	7	8	9	0	score	
456	S	L	н	A	Y	I	I	A	ĸ	V		30
584	L	I	I	v	T	<u>s</u>	I	A	L	L		28
169	ន	L	A	H	н	\$	8	A	A	L		27
438	N	L	Į	K	Y	D	L	Q	N	L		26
635	I	L	L	E	T	<u>Y</u>	K	R	K	I		26
6	K	L	L	A	F	<u>G</u>	F	A	F	L		25
195	Y	L	N	A	5	<u>E</u>	T	T	T	Ŀ		25
270	Ŋ	L	T	E	C	$\overline{\mathbf{K}}$	И	A	S	v		25
1175	G	I	F	С	A	<u>r</u>	L	N	L	L		25
292	T	ŗ	I	L	D	<u>v</u>	₽	P	G	٧		24
583	F	, T	I	I	V	$\underline{\mathbf{T}}$	ŝ	I	A	L		24
736	R	M	I	W	E	<u>Q</u>	K	A	T	V		24
1137	S	M	I	Q	V	<u>v</u>	K	Õ	K	L		24
32	G	L	T	T	A	<u>K</u>	M	Þ	8	V		23
575	F	A	L	I	A	<u>F</u>	L	A	F	L		23
590	ı	A	L	L	v	<u>v</u>	L	Y	K	I		23
643	ľ	I	A	D	E	Ģ	R	L	F	L		23
772	F	A S	F	G	D	<u>v</u>	V	V	K	I		23
1020	I	, I	M	S	Y	W	K	P	B	V		23
1046	Ç) M	Ι	F	Q	<u>R</u>	K	V	K	V		23
1095	\$	T	Y	Т	L	<u>R</u>	ν	F	E	L		23
1183		L										23
203	7	ľ	, s	P	S	<u>G</u>	S	Α	. ν	I		22
345	1	I	F	D	N	<u>K</u>	E	I	K	L		22

иккваткалг

HLEVEAGNTL

ALIAFLAFLI

DILPYDYNRV

HLLLKLRRRV

GLEAE<u>N</u> KVDV

KLRRQRCLMV

446

517

576

683

827

870

885

901 .	ILIHQ <u>A</u> LVBY	22
1201	ALRKA <u>R</u> PGMV	22
211	V I S T T T I A T T	21
424	Y I K E T <u>E</u> K D C L	21
578	IAFLA <u>F</u> LIIV	21
581	LAFLI <u>I</u> VT SI	21
585	IIVTS <u>I</u> ALLV	21
587	VTSIA <u>L</u> LVVL	21
593	г 🗘 л г Х <u>к</u> і х р г	21
649	RLFLAEFQSI	21
1180	LLNL <u>E</u> SAET	. 21
1291	SVNGP <u>A</u> SPAL	21
187	ITANT <u>S</u> DAYL	20
577	LIAFL <u>A</u> FLII	20
580	FLAFL <u>I</u> IVTS	20
586	IVTSI <u>A</u> LLVV	20
722	AAQGP <u>R</u> DETV	20
862	IGIDAMLEGL	20
1047	MIFQR <u>K</u> VKVI	20
1244	IEFDN <u>E</u> VDKV	20
2	YLWLK <u>L</u> LAFG	19
93	AFNTTGVSSV	19
177	ALPARŢSNTT	19
286	CTAPD <u>K</u> TLIL	19
448	KPYTK <u>Y</u> VLSL	19
492	s m T s D <u>N</u> s M H V	19
601	ргнкк <u>к</u> гсыг	19
652	LAEFQSIPRV	19
737	M I W E Q K A T V I	19
974	и ү грү <u>р</u> үмк∨	19
1079	QTYGD <u>I</u> EVDL	19
1186	SARTEEVVDI	19
1225	STYPAQNGQV	19
12	FAFLDTEVFV	18
34	TTAKMPSVPL	18
133	K L N P T P G S N A	18
572	YNSKALIAFL	18 18
685	LPYDY <u>N</u> RVEL	
803	KATGREVTHI	18
821	G V P E D P H L L L	18 18
846	PIVVH <u>C</u> SAGV	10

859	GTYIG <u>I</u> DAML	18
866	AMLEG <u>L</u> EAEN	18
877	V D V Y G Y V V K L	. 18
892	T M A Ó A B Y Ö A I	18
914	GETEV <u>N</u> LSEL	18
1032	AAQGP <u>L</u> KBTI	18
1127	QLPAE <u>P</u> KELI	18
1135	LISMI <u>O</u> VVKQ	18
128	SAANAKLNPT	17
202	TTLSP <u>S</u> GSAV	17
229	KYANI <u>T</u> VDYL	17
244	K L F T A <u>K</u> L N V N	17
288	APDKTLILDV	17
453	YVLSL <u>H</u> AYII	17
589	SIALL <u>V</u> VLYK	17
625	LMNVE <u>P</u> IHAD	17
770	GTRAFGDVVV	17
786	R C P D Y <u>I</u> I Q K L	17
829	LLKLR <u>R</u> RV NA	17
1015	YINAS FIMSY	17
1031	IAAQGPLKET	17
1053	VKVIVMLTEL	17
1133	KELIS <u>M</u> IQVV	17
1192	VVDIFQVVKA	17
1263	LGAPEKLPEA	17
73	S L S P D N T S T Q	16
87	SLDNA <u>S</u> AFNT	16
98	GVSSVQTPRL	16 16
167	TLSLAHHSSA	16
249	K L N V N <u>E</u> N V E C I L D V P <u>P</u> G V E K	16
294 376	FTNAS <u>K</u> IIRT	16
480	SAPPSQVWNM	16
511	GPHERYHLEV	16
619	RDDEKQLMNV	16
630	PIHAD <u>I</u> LLET	16
644	IADEGRLFLA	16
705	YINAS <u>Y</u> ID G F	16
789	D Y I I Q K L N I V	16
791	I I Q K L <u>N</u> I V N K	16
823	B B D B H T L T K T	16

940	SPLEA <u>E</u> FQRL	16
976	IPYDY <u>M</u> RVPL	16
1090	D T D K S <u>\$</u> T Y T L	· 16
1163	L L I H C <u>R</u> D G S Q	16
1174	T G I F C A L L N L	16
1178	CALLN <u>L</u> LESA	16
1182	N L L E S <u>A</u> E T E E	16
1193	V D I F Q <u>V</u> V K A L	16
1254	K Q D A N C V N P L	16
1283	s G T E G <u>P</u> E H s V	16
14	FLDTE <u>V</u> FV T G	15
37	K M P S V <u>P</u> L S S D	15
90	NASAF <u>N</u> TTGV	15
125	P S G S A <u>A</u> N A K L	15
259	G N N T C T N N E V	15
305	Q L H D C <u>T</u> Q V B K	15
320	C L K W K <u>N</u> I E T F	15
369	і гайи <u>н</u> кети	15
454	V I S L H <u>A</u> Y I I A	15
472	A M C H F <u>T</u> T K S A	15
533	KNCDF <u>R</u> VK D L	15
569	S T S Y N S K A L I	15
607	SCNLD <u>E</u> QQEL	15
624	Q L M N V E P I H A	15
627	NVEPIHADIL	15
651	FLAEFQSIPR	15
868	LEGLEAENKV	15
893	MVQVEAQYIL	15
906	ALVEYNQFGE	15
911	NQFGETEVNL	15
980	YNRVPLKHEL	15
1050	Q R K V K V I V M L	15
1087	D L K D T D K S S T	15
1116	YQYQYTNWSV	15 15
1179	ALLNL <u>L</u> ESAE FEQYQ <u>F</u> LYDV	15
1213	FLYDV <u>I</u> ASTY	15
1218	LAFGFAFLDT	14
10	FGFAFLDTEV	14
10 42	PLSSD <u>P</u> LPTH	14
	Q V S P D S L D N A	14
82	# 4 n r n m m m u	Y-4

106	H L P T H <u>A</u> D S Q T	14
137	TPGSN <u>A</u> ISDV	14
152	TASTF <u>P</u> TDPV	14
155	TFPTD <u>P</u> VSPL	14
161	V S P L T <u>T</u> T L S L	14
176	AALPA <u>R</u> TSNT	14
178	L P A R T <u>S</u> N T T I	14
205	SPSGS <u>A</u> VIST	14
241	KETKL <u>F</u> TAKL	14
246	F T A K L <u>N</u> V N R N	14
262	тстии <u>в</u> vниг	14
348	DNKEI <u>K</u> ГЕИГ	14
356	NLEPE <u>H</u> EYKC	14
394	QIIFC <u>R</u> SEAA	14
395	IIFCR <u>S</u> EAAĦ	14
416	S F H N F <u>T</u> L C Y I	14
461	IIAKVQRNGS	14
518	L E V E A G N T L V	14
557	G D Y P G E P F I L	14
616	L V E R D <u>D</u> E K Q L	14
636	LLETYKRKIA	14
688	DÝNRV <u>E</u> LSEI	14
721	I A A Q G P R D E T	14
828	LLKL <u>R</u> RR V N	14
883	V V K L R <u>R</u> Q R C L	14
898	AQYILIHQAL	14
899	O A I F I H O W F A	14
902	LIHQALVEYN	14
918	VNLSELHPYL	14
948	RLPSYRSWRT	14
1048	IFQRK <u>V</u> KVIV	14
1098	TLRVFELRB	14
1130	AEPKELISMI	14
1268	KLPEAKEQAE	14
4	W L K L L A F G F A	13
7	LLAFG <u>F</u> AFLD	13
13	A F L D T E V F V T	13
65 74	N D F S E <u>T</u> T T S L	13
74	LSPDN <u>T</u> ST Q V	13
101	з v Q т р <u>н</u>	13
154	0 1 2 2 1 7 2 4 9 2	13

208	GSAVI <u>S</u> TTTI	13
210	AVIST <u>T</u> TIAT	13
216	TIATT <u>P</u> SKPT	13
239	YNKET <u>K</u> LFTA	13
247	TAKLN <u>V</u> NENV	13
293	LILDV <u>P</u> PGVE	13
297	VPPGV <u>E</u> KFQL	13
317	TTICL <u>K</u> WK NI	13
381	KIIKT <u>D</u> F G S P	13
398	CRSEAAHQGV	13
426	K E T E K <u>D</u> C L N L	13
434	NLDKNLIKYD	13
477	TTKSA <u>P</u> PSQV	13
485	омим <u>т</u> из м т	13
509	R N G P H <u>E</u> R Y k L	13
525	T L V R N <u>E</u> S H K N	13
565	і _ь ння <u>т</u> з ч и з	13
591 ,	ALLVV <u>L</u> YKIY	13
595	A T X K I A D P H K	13
608	C N L D E Q Q E L V	13
609	NTDEOOETAE	13
676	Q N K N R Y V D I L	13
710	YIDGFKBPRK	13
738	IWEQKATVIV	13
766	SMEEG <u>T</u> RAFG	13
794	KLNIVŅKKEK	13
820	H G V P E D P H L L	13
831	KLRRRVNAFS	13
861	YIGID <u>A</u> MLEG	13
891	C L M V Q <u>V</u> E A Q Y Y I L I H Q A L V E	13 13
900 919	NLSELHPYLH	13
919	SELHPYLHNM	13
1021	IMSYWKPEVM	13
1030	MIAAQGPLKE	13
1030	ETIGDEWOMI	13
1044	F W Q M I F Q R K V	13
1057	V M L T E L K H G D	13
1077	GKQTYGDIEV	13
1119	QYTNW <u>S</u> VEQL	13
1145	K L P Q K <u>N</u> S S E G	13

1171	SQQTG <u>I</u> FCAL	13
1172	QQTGI <u>F</u> CALL	13
1189	· TEEVV <u>D</u> IFQV	13
1200	K A L R K A R P G M	13
1204	KARPG <u>M</u> VSTF	13
1217	Q F L Y D V I A S T	13
1222	VIASTYPAQN	13
1260	V N P L G A P B K L	13
27	TPSPTGLTTA	12
134	L M P T P <u>G</u> S N A I	12
162	SPLTT <u>T</u> LSLA	12
224	P T C D B K Y A N I	12
232	NITVD <u>Y</u> LY N K	12
236	DYLYN <u>K</u> ETKL	12
237	Y L Y N K E T K L F	12
243	T K L F T A K L N V	. 12
272	TECKN <u>A</u> SV SI	12
291	K T L I L <u>D</u> V P P G	12
306	LHDCTQVEKA	12
310	TQVEK <u>A</u> DT T I	12
432	CLNLD <u>K</u> NLIK	12
435	гокиг <u>т</u> кког	12
443	D L Q N L K P Y T K	12
460	YIIAK <u>V</u> QRNG	12
464	KVQRNGSAAM	12
579	AFLAF <u>L</u> IIVT	12
592	LLVVL <u>Y</u> KIYD	12
626	MNVEP <u>I</u> HADI	12
697	INGDAGSNYI	12
720	YIAAQGPRDE	12
740	EQKATVIVMV	12
790	AIIOKFNIAN	12
796	NIVNKKEKAT	12
800	KKEKA <u>T</u> GREV	12
839	FSNFF <u>S</u> GPIV	12
840	SNFFSGPIVV	12
853	A G V G R <u>T</u> G T ¥ I N K V D V <u>Y</u> G Y V V	12 12
875	RRQRC <u>L</u> MVQV	12
887	-	12
926 933	RDPPSEPSPL	12
933	V D E E O G E O E H	12

1028	EVMIA <u>A</u> QGPL	12
1029	V M I A A Q G P L K	12
1055	V I V M L <u>T</u> E L K H	12
1060	TELKH <u>G</u> DQEI	12
1082	GDIEV <u>D</u> LKDT .	12
1126	EQLPA <u>E</u> PKEL	12
1129	PAEPK <u>E</u> LISM	12
1184	LESAE <u>T</u> EEVV	12
1235	ккиинбвркі	12
24	Q s P T P <u>s</u> P T g L	11
29	SPTGL <u>T</u> TAKM	11
44	sspp <u>p</u> тнтт	11
51	HTTAFSPAST	11
79	т s т Q V <u>s</u> р D s L	11
92	SAFNT <u>T</u> GVSS	11
95	N T T G V <u>s</u> s V Q T	11
123	Q T F S G <u>S</u> A A N A	11
142	AISDV <u>P</u> GERS	11
146	V P G E R <u>S</u> T A S T	11
159	D P V S P <u>L</u> T T T L	11
164	ьттть <u>я</u> ьанн	11
190	· NTSDA <u>Y</u> LNAS	11
226	CDEKY <u>A</u> NITV	11
280	SISHN <u>S</u> CTAP	11
284	N S C T A P D K T L	11
303	KFQLHDCTQV	11
336	ITYRFQCGNM	11
343	GNMIFDNKEI	11
361	HEYKC <u>D</u> SEIL	11
387	FGSPGEPQII	11
421	TLCYIKETEK	11
433	L N L D K N L I K Y	11
445	QNLKPYTKYV	11
452	KYVLS <u>L</u> HAYI	11
462	I A K V Q <u>R</u> N G S A T v S M T <u>S</u> D N S M	11 11
490 408	SMHVKCRPPR	11
498 520	VEAGN <u>T</u> LVRN	11
520 541	DLQYSTDYTF	11
541 564	FILHHSTSYN	11
615	ELVERDDEKQ	11
013	7 1 1 1 1 2 2 2 X	11

628	VEPIH <u>A</u> DILL	11
631	I H A D I <u>L</u> L E T Y	11
675	n q n k n <u>r</u> y v d I	11
684	ILPYD <u>Y</u> NRVE	11
745	VIVMV <u>T</u> RCEE	11
797	IVNKKEKATG	11
813	Q F T S W P D H G V	11
864	IDAML <u>E</u> GLRA	11
867	M L E G L <u>E</u> A E N K	11
894	VQVEAQYILI	11
959	HIGNQ <u>E</u> ENKS	11
982	я v рьк <u>н</u> е ье м	11
1007	SDSEE <u>P</u> SK y I	11
1022	m s y w k <u>p</u> e v m i	11
1023	SYWKP <u>E</u> VMIA	11
1058	M L T E L <u>K</u> H G D Q	11
1106	H S K R K <u>D</u> S R T V	11
1134	E L I S M <u>I</u> Q V V K	11
1155	NKHHK <u>S</u> TPLL	11
1167	C R D G S Q T G I	11
1196	FQVVK <u>A</u> LR K A	11
84	зрргг биуач	10
88	LDNAS <u>A</u> FNTT	10
96	тт	10
109	THADSQTPSA	10
129	AANAKLNPTP	10
140	SNAIS <u>D</u> VPGE	10
144	SDVPGERSTA	10
157	PTDPV <u>S</u> PLTT	10
158	TDPVS <u>P</u> LTTT	10
175	S A A L P A R T S N	10
185	TTITANTSDA	10
193	DAYLNASETT	10
194	AYLNASETTT	10
209	SAVISTTTIA	10
233	ITVDYLYNKE	10
263	CTNNEVHNLT	10
278	S V S I S H N S C T	10
295	LDVPPGVEKF	10
309	CTQVEKADTT	10
312	VEKAD <u>T</u> TICL	10

319	I C L K W K N I E T	10
327	ETFTC <u>D</u> TQNI	10
353	K L E N L <u>E</u> P E R E	10
400	SEAAHQGVIT	10
402	A A H Q G <u>V</u> I T W N	10
430	KDCLN <u>L</u> DKNL	10
431	р с г и г Б к и г <u>1</u>	10
470	SAAMC <u>H</u> FTTK	10
484	s Q V W N <u>M</u> T V s M	10
516	YHLEV <u>B</u> AGNT	10
598	KIYDL <u>H</u> KKRS	10
641	KRKIA <u>D</u> EGRL	10
658	IPRVF <u>S</u> KFPI	10
661	V F S K F <u>P</u> I K E A	10
693	ELSEI <u>N</u> GDAG	10
729	ETVDD <u>F</u> WRMI	10
741	Q K A T V <u>I</u> V M V T	10
743	ATVIVMVTRC	10
747	VMVTR <u>C</u> EEGN	10
780	ктибн й всьр	10
795	LNIVNKKEKA	10
816	SWPDH <u>G</u> VPED	10
819	D H G V P E D P H L	10
830	LKLRRRVNAF	10
838	AFSNFFSGPI	10
855	VGRTGTYIGI	10
871	LEAENKVDVY	10
907	LVEYNQFGET	10
909	EYNQFGETEV	10
922	е т н р ч <u>г</u> н и м к и м к к в <u>р</u> р в в	10
929	SYRSW <u>R</u> TQHI	10
951 966	NKSKNRNSNV	10 10
1056	IVMLTELKHG	10
1092	DRSSTYTLRV	10
1154	GNKHH <u>K</u> STPL	10
1156	KHHKSTPLLI	10
1162	PLLIHCRDGS	10
1164	LIHCRDGSQQ	10
1177	FCALLNLLES	10
1194	DIFQVYKALR	10
		- •

1203	R K A R P <u>G</u> M V S T	10
1251	D K V K Q D A N C V	10
1256	DANCV <u>N</u> PLGA	10
1259	CVNPLGAPBK	10
39	P S V P L <u>S</u> S D P L	9
47	PLPTH <u>T</u> TAFS	9
59	STFER <u>E</u> NDFS	9
61	FEREN <u>D</u> FSET	9
111	ADSQT <u>P</u> SAGT	9
166	TILSLAHH S S	9
168	LSLAH <u>H</u> SSAA	9
181	R T S N T <u>T</u> I T A N	9
192	SDAYLMASET	9
197	NASETŢTLSP	9
201	TTTLS <u>P</u> SGSA	9
279	V S I S H <u>N</u> S C T A	9
285	S C T A P D K T L I	9
287	TAPDK <u>T</u> LILD	9
300	GVEKFQLHDC	9
318	TICLKWKNIE	9
324	KNIETFTCDT	9
325	NIETF <u>T</u> CDTQ	9
344	N M I F D <u>N</u> K E I K	9
352	IKLEN <u>L</u> EPEH	9
368	EILYN <u>N</u> HKFT	9
382	IIKTD <u>F</u> GSPG	9
401	EAAHQGVITW	9
408	ITWNPPQRSF	9
413	P Q R S F <u>H</u> N F T L	9
420	FTLCY <u>I</u> KETE	9
439	T I K Y D <u>L</u> Q N L K	9
442	урьом <u>г</u> кь х т	9
450	YTKYV <u>L</u> SLHA	9
455	LSLHAYIIAK	9
469	G S A A M C H F T T	9
471	A A M C H <u>F</u> T T K S	9
482	ррѕоушимту	9
559	Y P G E P <u>F</u> I L H H	9
568	H S T S Y N S K A L	9
610	LDEQQ <u>E</u> LV E R	9
622	EKQLM <u>N</u> VE P I	9

657	SIPRV <u>F</u> SKFP	9
691	R V E L S <u>E</u> I N G D	9
699	GDAGS <u>N</u> YINA	9
700	DAGSNYINAS	9
702	GSNYI <u>N</u> ASYI	9
746	IVMVT <u>R</u> CBEG	9
842	F F S G P <u>I</u> V V H C	9
849	V H C S A G V G R T	9
851	CSAGV <u>G</u> RTGT	9
863	GIDAM <u>L</u> EGLE	9
865	D A M L E G L E A E	· 9
873	AENKV <u>D</u> VY G Y	9
878	D V Y G Y <u>V</u> V K L R	9
897	EAQYILIHQA	9
967	ksknr <u>n</u> snvl	9
1025	WKPEVMIAAQ	9
1040	TIGDF <u>W</u> QMIF	9
1049	FQRKV <u>K</u> VIVM	9
1075	GEGKQ <u>T</u> YGDI	ç
1097	YTLRV <u>F</u> ELRH	9
1100	RVFELRHSKR	g
1140	Q V V K Q <u>K</u> L P Q K	9
1170	GSQQTGIFCA	9
1208	GMVST <u>F</u> EQYQ	9
1210	VSTFE <u>Q</u> YQFL	9
1211	STFEQYQFLY	9
1241	EDKIE <u>F</u> DNEV	9
1243	KIEFD <u>N</u> BVDK	!
1	MYLWL <u>K</u> L L A F	;
15	LDTEV <u>F</u> VTGQ	:
21	V T G Q S P T P S P	;
26		;
35		;
36		;
41	V P L S S D P L P T	
45		ı
63		
72		
121	D T Q T F <u>S</u> G S A A	
141		
143	I S D V P <u>G</u> E R S T	

		_
151	STAST <u>F</u> PTDP	8
163	PLTTTLSLAH	8
170	LAHHS <u>S</u> AALP	8
186	TITAN TSDAY	8
207	S G S A V <u>I</u> S T T T	8
215	TTIAT <u>T</u> PSKP	8
217	IATTP <u>S</u> KPTC	8
230	YANITÜDYLY	8
234	T V D Y L Y N K E T	8
238	LYNKE <u>T</u> KLPT	8
251	n v n e n v e c c n	8
314	KADTT <u>I</u> CLKW	8
329	FTCDTQNITY	8
337	TYRFQ <u>C</u> GNMI	8
351	EIKLE <u>N</u> LEPE	8
363	Y K C D S E I L Y N	8
373	NHKFT <u>N</u> AS KI	8
374	H K F T N <u>A</u> S K I I	8
386	D F G S P G E P Q I	8
389	SPGEP <u>Q</u> IIFC	8
406	G V I T W <u>N</u> P P Q R	8
407	VITWN <u>P</u> PQRS	8
419	N F T L C Y I K E T	8
459	AYIIAKVQRN	8
537	FRVKD <u>L</u> QYST	8
548	Y T F K A Y F H N G	8
556	И С D А Б <u>С</u> Е В В І	8
571	SYNSK <u>A</u> LI AF	8
582	AFLII <u>V</u> TSIA	8
588	TSIAL <u>L</u> VVLY	8
596	т ж кім <u>р</u> гн к к	8
634	DILLE <u>T</u> YK R K	8
638	ETYKR <u>K</u> IADE	8
673	P F N Q N K N R Y V	8
696	EINGD <u>A</u> GS N Y	8
715	KEPRK <u>Y</u> IAAQ	8
739	W E Q K A <u>T</u> V I V M	8
742	KATVI V M V T R	8
777	V V V K I <u>N</u> Q H K R	8
782	ионкксроч і	8
783	Q H K R C P D Y I I	8

792	I Q K L N <u>I</u> V N K K	8
806	GREVTHIQFT	8
811	HIQFT <u>S</u> WPDH	8
843	F S G P I V H C S	8
844	SGPIV <u>V</u> HCSA	8
848	v v н с s <u>A</u> g v g R	8
852	S A G V G R T G T Y	8
857	RTGTY <u>I</u> GIDA	8
889	Q R C L M <u>V</u> Q V E A	8
895	QVEAQYILIH	8
975	v т р ұ р <u>ч</u> м к v р	8
984	рткне <u>т</u> вмзк	8
988	ELEMS <u>K</u> ESEH	8
024	Y W K P E <u>V</u> M I A A	8
1036	PLKET <u>I</u> GDFW	8
(051	R K V K V <u>I</u> V M L T	8
1062	LKHGDQEÏCA	8
1083	DIEVD <u>T</u> KDTD	8
1216	YQFLY <u>D</u> VIAS	8
1227	YPAQN <u>G</u> QVKK	8
1246	$\mathbf{F} \mathbf{D} \mathbf{N} \mathbf{E} \mathbf{V} \mathbf{\underline{D}} \mathbf{K} \mathbf{V} \mathbf{K} \mathbf{Q}$	8
1262	PLGAP <u>E</u> KLPE	8
1264	G A P E K <u>L</u> P E A K	8
1294	GPASP <u>A</u> LNQG	8
9	AFGFA <u>F</u> LDTE	7
25	SPT PS <u>P</u> TGLT	7
40	SVPLS <u>S</u> DPLP	7
43	LSSDP <u>L</u> PTHT	7
52	TTAFS <u>P</u> ASTF	7
70	TTTSLSPDNT	7
71	TTSLSPDNTS	7
100	SSVQTPHLPT	7
113	SQTPSAGTDT	7
171	A H H S S <u>A</u> A L P A	7
180	ARTSN <u>T</u> TITA	7
182	T S N T T <u>I</u> T A N T	7
206	PSGSA <u>V</u> ISTT	7
218	ATTPS <u>K</u> PT C D	7
225	TCDEKYANIT	7
255	и ч в с с <u>й</u> и т с т	7
275	K N A S V <u>S</u> I S H N	7

321	LKWKN <u>I</u> ETFT	7
335	NITYR <u>F</u> QC G N	7
340	FQCGN <u>M</u> IFDN	7
367	SEILY <u>N</u> NHKF	7
370	LYNNH <u>K</u> FTNA	7
377	TNASK <u>I</u> IKTD	7
399	RSEAAHQGVI	7
440	IKYDLQNLKP	7
451	T K Y V L <u>S</u> L H A Y	7
458	H A Y I I A K V Q R	7
463	AKVQR <u>N</u> GSAA	7
476	FTTKS <u>A</u> PPSQ	7
479	K S A P P <u>S</u> Q V W N	7
481	APPSQVWNMT	7
488	n m r v s <u>m</u> r s d n	7
513	HERYH <u>L</u> EVEA	7
530	E S H K N <u>C</u> D F R V	7
540	к р ь о ү <u>з</u> т р ү т	7
545	STDYT <u>F</u> KAYF	7
561	G E P F I <u>L</u> H H S T	7
604	K R R S C <u>N</u> L D B Q	7
633	ADILLETYKR	7
646	DEGRL <u>F</u> LAEF	7
655	FQSIP <u>R</u> VF5K	7
660	R V F S K <u>F</u> P I K E	7
663	SKFPI <u>K</u> EARK	7
666	PIKEA <u>R</u> KPFN	7
692	VELSE <u>I</u> NGDA	7
712	DGFKBPRKYI	7
713	G F K E P R K Y I A	7
714	FREPRKYIAA	7
734	FWRMI <u>W</u> BQKA	7
758	N R C A E Y W P S M	7
768	EEGTRAFGDV	7
771	TRAFGDVVVK	7 7
785	KRCPDYIIQK	7
788	PDYIIQKLNI	
804	ATGREVTHIQ	7 7
841	NFFSG <u>P</u> IVVH	7
858	T G T Y I G I D A M	7
876	к v D V Y <u>G</u> Y V v К	,

880	YGYVV.KLRRQ	7
884	VKLRR <u>Q</u> RCLM	7
890	R C L M V Q V E A Q	7
896	VEAQY <u>I</u> LIEQ	7
912	Q F G E T E V N L S	7
917	EVNLS <u>E</u> LHPY	7
942	LEAEFQRLPS	7
983	VPLKH <u>E</u> LB M S	7
1009	SEEPS <u>K</u> YI N A	7
1013	SKYIN <u>A</u> SFIM	7
1035	GPLKE <u>T</u> IGDF	7
1052	к укуі <u>у</u>мьт в	7
1054	K V I V M <u>L</u> T E L K	7
1063	KHGDQ <u>E</u> ICAQ	7
1068	EICAQ <u>Y</u> WGRG	7
1118	Y Q Y T N <u>W</u> S V E Q	7
1120	Y T N W S <u>V</u> E Q L P	7
1128	LPAEP <u>K</u> BLIS	7
1138	MIQVV <u>K</u> QKLP	7
1152	SEGNK <u>H</u> HKST	7
1159	K S T P L <u>L</u> I H C R	7
1187	AETEB <u>V</u> VDIF	7
1190	EEVVD <u>I</u> FQ V V	7
1220	Y D V I A <u>S</u> T Y P A	7
1221	DVIAS <u>T</u> YPAQ	7
1257	ANCVN <u>P</u> LGAP	7
1275	Q A E G S <u>E</u> P T S G	7
1276	AEGSE <u>P</u> TSGT	7
18	EVFVT <u>G</u> QSPT	6
20	FVTGQ <u>S</u> PTPS	6
23	GQSPT <u>P</u> SP T G	6
54	AFSPA <u>S</u> TFER	6
56	SPASTFEREN	6
80	STQVS <u>P</u> DSLD	6
102	VQTPHLPTHA	6
103	Q T P H L P T H A D	6
114	Q T P S A G T D T Q	6
117	SAGTDTQTFS	6
119	GTDTQ <u>T</u> FSGS	6
132	AKLNPTPGSN	6
145	DVPGE <u>R</u> STAS	6

156	F P T D P V S P L T	6
172	H H S S A A L P A R	б
173	H S S A A <u>L</u> P A R T	б
174	SSAAL <u>P</u> ARTS	6
188	TANTSDAYLN	6
189	ANTSD <u>A</u> YLNA	6
214	T T T I A <u>T</u> T P S K	6
250	L N V N E <u>N</u> V E C G	6
253	N E N V E <u>C</u> G N N T	6
261	N T C T N <u>N</u> E V H N	6
264	TNNEV <u>H</u> NLTE	6
283	H N S C T <u>A</u> P D K T	6
350	KEIKГĒИГВЬ	6
354	LENLEPEHEY	6
364	K C D S E I L Y N N	6
384	KTDFGSPGEP	6
493	м т S D N <u>s</u> м н v к	6
495	SDNSMHVKCR	6
522	AGNTLURNES	6
524	N T L V R <u>N</u> E S H K	6
538	к у крьду зт р	6
543	QYSTDYTFKA	6
554	FHNGDYPGEP	6
567	H H S T S Y N S K A	6
570	T S Y N S K A L I A	6
574	SKALI <u>A</u> FLA F	6
594	V V L Y K I Y D L H	6
617	V E R D D E K Q L M	6
656	Q S I P R <u>V</u> F S K F	6
670	ARKPF <u>N</u> QNKN	6
679	NRYVD <u>I</u> LPYD	6
681	YVDILPYDYN	6
687	YDYNR <u>V</u> ELSE	6
695	SEING <u>D</u> AGSN	6
701	AGSNYINASY	6
725	G P R D E T V D D F	6
732	D D F W R M I W B Q	6 6
744	TVIVM <u>V</u> TRCE	
749	V T R C E E G N R N	6
769	EGTRAFGDVV	6 6
773	A F G D V <u>V</u> V K I N	Ò

775	ор v v v <u>к</u> і м о н	6
822	A B E D B H T T T K	6
837	n a f s n <u>f</u> f s g p	6
847	I V V H C S A G V G	6
854	GVGRTGTYIG	6
856	GRTGTYIGID	6
874	ENKVD <u>V</u> XGYV	6
882	YVVKLRRQRC	6
886	LRRQR <u>C</u> LM Y Q	6
905	Q A L V E Y N Q F G	6
932	KRDPP <u>S</u> EPSP	6
935	PPSEP <u>S</u> PLEA	6
937	SEPSP <u>L</u> EABF	6
941	PLEAEFQRLP	6
943	EARFQRLPSY	6
954	SWRTQ <u>H</u> IGNQ	6
956	R T Q H I G N Q E E	6
970	NRNSN <u>V</u> IPYD	6
978	Y D Y N R V P L K H	6
985	L K H E L <u>E</u> M S K E	6
987	H R L E M <u>S</u> K E S E	6
990	EMSKR <u>S</u> EHDS	6
1042	G D F W Q M I F Q R	6
1061	е т кно <u>о</u> оетс	6
1071	AQYWG <u>E</u> GKQT	6
1103	ELRHS <u>K</u> RKDS	6
1113	R T V Y Q Y Q Y T N	6
1121	TNWSV <u>E</u> QLPA	6
1122	NWSVEQLPAE	6
1123	WSVEQ <u>L</u> PAEP	6
1132	PKELI <u>S</u> MIQV	6
1136	I S M I Q <u>V</u> V K Q K	6
1141	V V K Q K <u>L</u> P Q K N	6
1144	Q K L P Q <u>K</u> N S S E	6
1151	s s e g n <u>k</u> h h k s	6
1160	STPLL <u>I</u> HCRD	6
1165	I H C R D G S Q Q T	6
1181	LNLLESAETE	6
1198	V V K A L <u>R</u> K A R P	6
1214	EQYQF <u>L</u> YDVI	6
1223	I A S T Y P A Q N G	6

		_
1228	PAQNGQVKKN	6
1238	NHQEDKIEFD	6
1281	PTSGTEGPEH	6
1284	G T E G P E H S V N	6
3	LWLKL <u>L</u> AFGF	5
5	LKLLA <u>F</u> GFAF	5
33	LTTAKMPSVP	5
49	PTHTAFSPA	5
53	TAFSP <u>A</u> STFE	5
68	SETTT <u>S</u> LSPD	5
78	n T s T Q <u>V</u> S P D S	5
110	H A D S Q T P S A G	5
120	T D T Q T <u>F</u> S G S A	5
131	NAKLN <u>P</u> TPGS	5
136	PTPGS <u>N</u> AISD	5
179	PARTS <u>N</u> TTIT	5
184	N T T I T A N T S D	5
198	ASETT <u>T</u> LSPS	5
213	STTTIATTPS	5
222	SKPTC <u>D</u> EKYA	5
231	ANITV <u>D</u> YLYN	5
248	A R L N V <u>N</u> E N V E	5
256	у в с в и <u>и</u> т с т и	5
265	N N E V H <u>N</u> L T E C	5
268	V H N L T <u>E</u> C K N A	5
271	LTECK <u>N</u> ASVS	5.
276	. nasvs <u>i</u> shns	5
277	A S V S I <u>S</u> H N S C	5
346	I F D N K <u>E</u> I K L E	5
347	F D N K E <u>I</u> K L E N	5
360	E H E Y K <u>C</u> D S E I	5
371	Y N N H K <u>F</u> T N A S	5
380	SKIIK <u>T</u> DF G S	5
393	PQIIF <u>C</u> RSEA	5
422	L C Y I K E T E K D	5
427	ETEKDCLNLD	5
444	LQNLK <u>P</u> YTKY	5
468	NGSAA <u>M</u> CHFT	5
521	EAGNT <u>L</u> VRNE	5
526	L y R N E <u>S</u> H K N C	5
527	V R N E S <u>H</u> K N C D	5

532	H K N C D <u>F</u> R V K D	5
551	K A Y F H N G D Y P	5
566	L H H S T S Y N S K	5
645	ADEGR <u>L</u> FLAE	5
678	KNRYV <u>D</u> ILPY	5
707	NASYIDGFKE	5
709	SYIDG <u>F</u> KEPR	5
730	T V D D F <u>w</u> R M I W	5
735	WRMIWEQKAT	5
759	K C A E Y <u>W</u> P S M E	5
761	A E Y W P <u>S</u> M E E G	5
762	$\mathbf{E} \mathbf{Y} \mathbf{W} \mathbf{P} \mathbf{S} \mathbf{\underline{M}} \mathbf{E} \mathbf{E} \mathbf{G} \mathbf{T}$	5
809	VTHIQ <u>F</u> TSWP	5
814	FTSWP <u>D</u> HG V P	5
815	TSWPD <u>H</u> GVPE	5
835	RVNAF <u>S</u> NFFS	5
961	G N Q E E <u>N</u> K S K N	5
968	sknrn <u>s</u> nvip	5
969	K N R N S <u>N</u> V I P Y	5
993	Keseh <u>d</u> sd e s	5
995	sehds <u>d</u> es s d	5
1002	SSDDD <u>S</u> DSEE	5
1003	SDDDSDSEEP	5
1018	ASFIM <u>S</u> YWKP	5
1059	LTBLK <u>H</u> GDQE	5
1069	ICAQYWGEGK	5
1070	C A Q Y W <u>G</u> E G K Q	5
1072	O A M C B G K O L A	5
1080	TYGDI <u>E</u> VDLK	5
1081	X & D I E A D P K D	5
1089	K D T D K <u>s</u> s T Y T	5
1093	K S S T Y <u>T</u> L R V F	5
1102	FELRH <u>S</u> KRKD	5
1109	R K D S R T V Y Q Y	5
1112	s r T V Y Q Y Q Y T	5
1114	TVYQY <u>Q</u> YTNW	5
1124	S V E Q L <u>P</u> A E P K	5
1173	Q T G I F <u>C</u> A L L N	5
1209	MVSTF <u>E</u> QY Q F	5
1215	QYQPLYDVIA	5
1233	Q V K K N <u>N</u> H Q E D	5

1248	NEVDK <u>V</u> KQDA	5
1265	APEKL <u>P</u> EAKE	5
1267	EKLPE <u>A</u> KEQA	5
1269	L P E A K <u>E</u> Q A e G	5
1273	K E Q A E <u>G</u> S E P T	5
1286	EGPEHSVNGP	5
1292	V N G P A <u>s</u> P A L N	5
19	V F V T G <u>Q</u> S P T P	4
22	TGQSP <u>T</u> PSPT	4
46	D P L P T <u>H</u> T T A F	4
83	VSPDSLDNAS	4
86	D S L D N <u>A</u> S A F N	4
115	TPSAG <u>T</u> DTQT	4
118	AGTDTQTFSG	4
124	T F S G S <u>A</u> A N A K	4
127	G S A A N <u>A</u> K L N P	4
130	ANAKL <u>N</u> PTPG	4
139	G S N A I <u>s</u> D V p G	4
165	TTTLSLAHRS	4
183	SMTTI <u>T</u> ANTS	4
191	T S D A Y L N A S E	4
196	LNASE <u>T</u> TTLS	4
199	S R T T T L S P S G	4
204	L S P S G <u>S</u> A V I S	4
219	TTPSK <u>P</u> TCDE	4
235	и р иг и и квик	4
269	HNLTECKNAS	4
281	I S H N S C T A P D	4
282	SHNSCTAPDK	4
296	DVPPG <u>V</u> EKFQ	4
308	DCTQVEKADT	4
313	EKADTTICLK	4
315	ADTTICLKWK	4
316	DTTICLKWKN	4
328	T P T C D T Q N I T	4
330	TCDTQNITYR	4
342	CGNMIFDNKE	4
372	NNHKFTNASK	4
378	NASKI <u>I</u> KTDF	4
383	IKTDFGSPGE	4
396	I F C R S <u>E</u> A A H Q	4

403	AHQGV <u>I</u> TWNP	4
437	K M T I K X D T O N	4
441	K A D T Ö W T K b A	4
486	V W N M T <u>V</u> S M T S	4
489	$\mathtt{M} \ \mathtt{T} \ \mathtt{V} \ \mathtt{S} \ \mathtt{M} \ \underline{\mathtt{T}} \ \mathtt{S} \ \mathtt{D} \ \mathtt{N} \ \mathtt{S}$	4
494	T S D N S M H V K C	4
503	$C R P P R \underline{D} R N G P$	4
552	AYFHN <u>G</u> DYPG	4
553	ч ғ н и с <u>р</u> ч р с в	4
597	YKIYDĿHKKR	4
599	IYDLH <u>K</u> KR 8 C	4
600	$YDLHK\underline{K}RSCN$	4
614	Q E L V E <u>R</u> D D E K	4
623	KQLMN <u>V</u> EPIH	4
629	EPIHA <u>D</u> ILLE	4
632	HADILĒETYK	4
650	L F L A E <u>F</u> Q S I P	4
668	KEARK <u>P</u> FNQN	4
682	V D I L P Y D Y N R	4
694	L S E I N G D A G S	4
703	зиліи <u>ў</u> загр	4
706	I N A S Y <u>I</u> D G F K	4
708	ASYID <u>G</u> FK B P	4
719	KYIAA <u>O</u> GPRD	4
723	AQGPRDETVD	4
751	RCEEG <u>N</u> RNKC	4
752	CEEGN <u>R</u> NKCA	4
760	CAEYW <u>P</u> SMRE	4
763	YWPSM <u>E</u> EGTR	4
764	WPSMEEGTRA	4
801	KEKAT <u>G</u> RE V T	4
832	LRRVNAFSN	4
836	VNAFS <u>N</u> FFSG	4
845	GPIVV <u>H</u> CSAG	4
860	TYIGIDAMLE	4
888	RORCLMVOVE	4
908	V E Y N Q F G E T E	4
947	QRLPSYRSWR QHIGNQBENK	4
958	I C N O E E N K S K O H I C N O E E N K	4
960 1016	INASFIMSYW	4
1016	THESTÄMSTH	~

1017	N	A	s	F	I	M	s	Y	W	ĸ		4
1033	A	Q	G	Þ	L	<u>K</u>	E	T	I	G		4
1038	ĸ	E	T	I	G	₽	F	W	Q	M		4
1073	Y	Ŵ	G	B	G	<u>K</u>	Q	T	Y	G		4
1086	v	D	L	K	D	$\underline{\mathbf{T}}$	ם	к	s	S		4
1088	L	ĸ	D	T	D	<u>K</u>	Ş	Ş	T	Y		4
1099	L	R	V	F	E	<u>r</u>	R	H	S	ĸ		4
1104	L	R	Ħ	S	K	$\underline{\mathtt{R}}$	K	D	3	R		4
1105	R	H	S	K	R	<u>K</u>	D	ŝ	R	T		4
1125	v	E	Q	L	P	<u>A</u>	E	P	K	E		4
1148	Q	ĸ	N	ŝ	8	<u>E</u>	G	N	ĸ	H		4
1157	н	H	K	s	T	<u>P</u>	L	L	I	H		4
1158	H	ĸ	8	T	P	$\underline{\mathbf{r}}$	L	I	H	C		4
1191	E	V	V	D	I	<u>F</u>	Q	v	V	K		4
1197	Q	v	v	K	A	$\bar{\mathbf{r}}$	R	K	A	R		4
1205	A	R	P	G	М	<u>v</u>	8	T	F	E		4
1229	A	Q	N	G	Q	$\underline{\mathbf{v}}$	K	K	N	И	•	4
1252	K	V	K	Q	D	<u>A</u>	N	C	v	N		4
1253	Λ	K	Q	D	A	\overline{N}	C	V	N	P		4
1271	E	A	K	K	Q	A	E	G	8	È		4
1274	B	Q	A	Ξ	G	<u>s</u>	E	P	T	s		4
1278	G	8	E	P	T	<u>s</u>	G	T	E	G		4
1285	T	K	G	P	E	<u>H</u>	S	V	N	G		4
1287	G	P	E	H	\$	$\underline{\mathtt{v}}$	N	G	P	A		4
1290	H	8	v	Ŋ	Ġ	<u>P</u>	A	S	P	A	•	4
1295	P	A	s	P	A	<u>L</u>	N	Q	G	S		4
48	L	P	T	H	T	T	A	F	S	₽		3
67	F	5	Ē	Τ	T	<u>T</u>	S	L	\$	P		3
89	D	И	A	\$	A	F	И	T	T	G		3
91	A	S	Α	F	N	T	T	G	v	S		3
105				P								3
107				H		_						3
116				G								3
135				P								3
160	P			P								3
212	I			T								3
245				A								3
267				N								3
274				A							,	3
301				F								3
304	F	á	مل	H	מ	<u>C</u>	T	Q	V	E		3

311	Q V E K A D T T I C	3
332	D T Q N I T Y R F Q	3
338	YRFQCGNMIF	3
357	LEPEHEYKCD	3
365	C D S E I <u>L</u> Y N N H	3
385	T D F G S P G E P Q	3
388	GSPGEPQIIF	3
409	TWNPPQRSFH	3
418	H N F T L C Y I K E	3
429	E K D C L N L D K N	3
447	T K B A L K A A F &	3
465	V Q R N G <u>S</u> A A M C	3
466	Q R N G S <u>A</u> A M C H	3
474	C H F T T K S A P P	3
487	WMMTVSMTSD	3
500	HVKCR <u>P</u> PRDR	3
502	K C R P P R D R N G	3
514	ERYHL <u>E</u> V EA G	3
515	RYHLB <u>V</u> EAGN	3
536	D F R V K <u>D</u> L Q Y S	3
542	LQYSTDYTFK	3
560	P G E P F <u>I</u> L H H S	3
573	N S K A L <u>I</u> A F L A	3
611	DEQQELVERD	3
640	YKRKIADEGR	3
653	A E F Q S I P R V F	3
664	KPPIKEARKP	3
672	KPFNQNKNRY	3
711	IDGFKEPRKY	3
748	MVTRCEEGNR	3
776	DVVVKINQHK	3
778	V V K I N Q H K R C	3
779	V K I N Q H K R C P	3
781	INQHKRCPDY	3 3
793	Q K L N I V N K K E	
802	EKATG <u>R</u> EV TH 1 Q F T S W P D H G	3 3
812 826	PHTFFFBBB TÖLLZEBBB	3
826	I H O Y F A E A M O	3
903 904	HQALVEYNQF	3
904	FGETEVNLSE	3
713		3

923	гньлг <u>н</u> имкк	3
927	L H N M K K R D P P	3
936	PSEPS <u>P</u> LEAE	3
944	ABFQR <u>L</u> PSYR	3
946	FQRLP <u>E</u> YR8W	3
949	LPSYR <u>S</u> WRTQ	3
952	YRSWR <u>T</u> QHIG	3
973	SNVIPYDYNR	3
979	DYNRV <u>P</u> LKHE	3
989	LRMSK <u>E</u> SEHD	3
991	M S K E S <u>E</u> H D S D	3
999	s d E s s <u>d</u> d d s d	3
1005	D D S D S <u>E</u> E P S K	3
1010	EEPSKYINAS	3
1012	PSKYI <u>N</u> ASFI	3
1014	KYINA <u>S</u> FIMS	3
1019	SFIMSYWKPE	3
1065	G D Q E I <u>C</u> A Q Y W	3
1067	QEICAQYWGE	3
1074	W G E G K Q T Y G D	3
1078	KQTYGDIEVD	3
1084	I E V D L <u>K</u> D T D K	3
1085	EVDĽK <u>D</u> TD K S	3
1108	K R K D S R T V Y Q	3
1139	I Q V V K Q K L P Q	3
1143	кокгьокие в	3
1146	ьроки <u>я</u> веси	3
1150	изѕес <u>и</u> кн и к	3
1166	H C R D G S Q Q T G	3
1176	IFCALLNLLE	3
1185	ESAET <u>E</u> EVVD	3
1195	I F Q V V <u>K</u> A L R K	3
1199	V K A L R <u>K</u> A R P G	3
1242	рківь <u>р</u> ивль	3
1255	Q D A N C <u>V</u> N P L G	3
1261	NPLGA <u>P</u> EKLP	3
1272	AKEQA <u>E</u> GSEP	3
1279	S B P T S <u>G</u> T E G P	3
11	GFAFL <u>D</u> TEVF	2
16	D T E V F <u>V</u> T G Q S	2
31	T G L T T A K M P S	2

62	EREND <u>F</u> SETT	2
75	spont <u>s</u> tqvs	2
76	PDNTS TQV SP	2
77	ритетблерр	2
99	V S S V Q <u>T</u> P H L P	2
104	TPHLP <u>T</u> HADS	2
150	R S T A S <u>T</u> F P T D	2
220	TPSKP <u>T</u> CDEK	2
223	KPTCD <u>E</u> KYAN	2
254	вичвс <u>а</u> иитс	2
258	C G N N T C T N N B	2
322	K W K N I <u>E</u> T F T C	2
334	Q n I T Y <u>R</u> F Q C G	2
390	P G E P Q <u>I</u> I F C R	2
397	FCRSB <u>A</u> AHQG	2
410	w и р р Q <u>R</u> s г н и	2
412	PPQRS <u>F</u> HNFT	2
415	RSFHN <u>F</u> TLCY	2
417	FHNFT <u>L</u> CYIK	2
457	L H A Y I <u>I</u> A K V Q	2
491	V s M T s <u>p</u> n s м н	2
508	DRNGPHERYH	2
523	G n T L v <u>R</u> n e s h	2
535	CDFRVKDLQY	2
544	Y S T D Y <u>T</u> F K A Y	2
546	TDYTF <u>K</u> AYFH	2
550	FKAYF <u>H</u> NGDY	2
602	LHKK'RSCNLD	2
621	рвкогйилкьь	2
642	RKIAD <u>E</u> GRLF	2
648	GRLFL <u>A</u> EFQS	2
665	FPIKE <u>A</u> RKPF	2
674	F N Q N K <u>N</u> R Y V D	2
680	RYVDI <u>L</u> PY D Y	2
689	YNRVELSEIN	2
690	NRVELSEING	2
704	N Y I N A S Y I D G	2
724	QGPRDETVDD	2
728	DETVDDFWRM	2
750	TRCEEGNRNK	2
754	EGNRNKCAEY	2

		_
756	n r n k c <u>a</u> e y w p	2
767	M E E G T <u>R</u> A F G D	2
805	T G R E V T H I Q F	2
807	REVTHIQFTS	2
808	EVTHIQFTSW	2
810	THIQF <u>T</u> SWPD	2
850	H C S A G V G R T G	2
872	EAENK <u>V</u> DV Y G	2
920	rserн <u>в</u> агни	2
924	нругн <u>и</u> мк к к	2
928	HNMKK <u>R</u> DPPS	2
931	K K R D P <u>P</u> S E P S	2
953	RSWRTQHIGN	2
957	TQHIG <u>M</u> QEEN	2
981	NRVPLKHBLE	2
1026	K P E V M <u>I</u> A A Q G	2
1064	H G D Q E <u>I</u> C A Q Y	2
1094	SSTYTLRVFE	2
1107	S K R K D <u>S</u> R T V Y	2
1161	TPLLI <u>H</u> CRDG	2
1188	ETEEV <u>V</u> DIFQ	2
1206	R P G M V S T F E Q	2
1219	LYDVI <u>A</u> STYP	2
1224	ASTYP <u>A</u> QNGQ	2
1232	солкк <u>и</u> ино е	2
1237	N N H Q E <u>D</u> K I B F	2
1249	EVDKV <u>K</u> QDAN	2
1250	VDKVKQDANC	2
1258	NCVNP <u>L</u> GAPE	2
17	твугу <u>т</u> дорг	1
50	THTTAFSPAS	1
55	FSPASTFERE	1
57	PASTF <u>E</u> REND	1
58	ASTFE <u>R</u> ENDF	1
60	TFERENDFSE	1
66	DFSET <u>T</u> TSLS	1
69	ETTTS <u>L</u> SPDN	1
81	т Q v s р <u>р</u> ѕ ∟ р и	1
108	PTHAD <u>S</u> QTPS	1
112	D S Q T P <u>S</u> A G T D	1
122	TQTFS <u>G</u> SAAN	1

126	SGSAANAKLN	
148	GERST <u>A</u> STFP	
149	ERSTASTFFT	
153	ASTFP <u>T</u> DPVS	
200	ETTTL <u>S</u> PSGS	
227	DEKYA <u>N</u> IT V D	
323	W K N I E <u>T</u> F T C D	
333	томгтукгос	
355	ENLEP <u>E</u> HEYK	
359	PEHEY <u>K</u> CDSE	
379	ASKII <u>K</u> TDFG	
391	G E P Q I <u>I</u> F C R S	
404	носкітмирь	
405	Q G V I T <u>W</u> N P P Q	
411	n p p Q R S F H N F	
423	CYIKE <u>T</u> EKDC	
425	I K E T E <u>K</u> D C L N	
428	TEKDC <u>L</u> NLDK	
497	измну <u>к</u> скър	
499	M E V K C R P P R D	
501	V K C R P <u>P</u> R D R N	
510	и с в н в <u>в</u> и н г в	
519	E V E A G N T L V R	
531	SHKNCDFRVK	
539	V K D L Q Y S T D Y	
549	TFKAYFHNGD	
555	нисру <u>г</u> се р г	
558	DYPGE <u>P</u> FILH	
563	PFILHHSTSY	
605	KRSCN <u>L</u> DEQQ	
637	LETYKRKIAD	
639	TYKRK <u>I</u> ADEG	
667	IKEARKPFNQ	
669	EARKP <u>F</u> NQNK	
677	NKNRYVDILP	
698	NGDAG <u>S</u> NYIN	
718	RKYIAAQGPR	
716 755	GNRNK <u>C</u> ABYW	
765	PSMEEGTRAF	
703 774	F G D V V V K I N Q	
77 4 798	VNKKE <u>K</u> ATGR	
170	ANVVEVVIA	

799	N	I	ζ :	K	E	ĸ	<u>A</u>	T	G	R	E	1	1
834	R	. E	\$.	V	N	Ą	<u>F</u>	s	N	F	F	•	1
879	V	. 3	7 (G	Y	v	$\underline{\mathbf{v}}$	ĸ	L	R	R	1	1
881	G	3	ζ,	V	V	K	Ē	R	R	Q	R	2	1
910	Y	ľ	1	Q	F	G	E	T	E	v	N	T	1
916	T	F	•	V	N	L	<u>s</u>	E	L	H	P	•	1
930	М	F	C 1	K	Ŕ	D	<u>P</u>	P	S	E	₽		1
971	R	. 1	1	S	N	V	Ī	₽	Y	D	Y	:	1
972	N	2	3]	N	٧	I	<u>P</u>	Y	D	¥	N	r	1
977	P	,	r	D	Y	N	<u>R</u>	٧	P	L	K	ī	1
986	K	I	1	E	L	E	M	S	K	E	s	ı	1
992	s	ľ	C 1	Е	S	E	$\overline{\mathbf{H}}$	D	8	D	E	:	1
997	H	Ι) !	8	D	E	<u>s</u>	S	D	D	D		1
998	D	5	3]	D	E	S	9	D	D	D	8	•	1
1006	D	8	3 3	D	S	E	E	P	S	K	Y		1
1008	D	5	3 1	È	E	P	<u>3</u>	K	Y	I	N	1	1
1011	E	I	? !	S	K	Y	Ī	N	A	8	F	•	1
1034	Q	G	•	Þ	L	K	E	T	I	G	D	1	1
1037	ľ	F		B	T	I	<u>G</u>	D	F	W	Q	!	1
1041							<u>Q</u>						1
1110							<u>v</u>						1
1115	V	. 3	7	Q	Y	Q	<u>Y</u>	T	N	W	8	·	1
1202	L	F	?]	K	A	R	<u>P</u>	G	M	V	ន	•	1
1230							<u>K</u>						1
1231	N	(3 (Q	V	K	K	N	И	H	Q	2	1
1236							E						1
1247							<u>K</u>						1
1277	E	G	,	S	E	P	T	S	G	T	E	}	1
1289							G						1
1293							<u>P</u>						1
30							T						0
38							Ť						0
94							<u>v</u>						0
97							<u>y</u>						0
221							<u>C</u>						0
228							Ī						0
240							<u>r</u>						0
252							<u>E</u>						0
266							<u>r</u>						0
273							<u>\$</u>						0
289	P		,		1	ш	Ī	L	ט	٧	אַ	•	0

290	рктьі <u>ь</u> рурр	0
299	PGVEK <u>F</u> QL H D	0
302	e k f Q L <u>H</u> D C T Q	0
307	H D C T Q <u>V</u> E K A D	0
326	I E T F T C D T Q N	0
331	C D T Q N <u>I</u> T Y R F	0
339	к в О С С <u>й</u> м і в р	0
341	Q C G N M <u>I</u> F D N K	0
349	NKEIK <u>L</u> ENLE	0
375	K F T N A S K I I K	0
436	DKNLI <u>K</u> YD L Q	0
449	PYTKY <u>V</u> LSLH	0
467	RNGSA <u>A</u> MCHF	0
473	M C H F T <u>T</u> K S A P	0
475	HPTTK <u>S</u> APPS	0
478	TKSAP <u>P</u> SQVW	0
504	RPPRD <u>R</u> NGPH	0
506	PRDRNGPHER	0
507	RDRNGPHERY	0
512	PHERYHLEVE	0
529	NESHK <u>N</u> CDFR	0
562	R P F I L <u>H</u> H S T S	0
603	HKKŔŚ <u>C</u> NLDE	0
60 6	к з с и г <u>о</u> е б б е	0
662	FSKFP <u>I</u> KBAR	0
686	PYDYN <u>R</u> VELS	0
731	V D D F W R M I W E	0
733	D F W R M <u>I</u> W E Q K	0
784	HKRCPDYIIQ	0
817	WPDHGVPEDP	0
824	е ррн	0
825	ррнгг кгк	0
833	RRRVNÄFSNF	0
869	EGLEAENKVD	0
915	ETEVNLSELH	0
934	DPPSE <u>P</u> SPLE	0
955	WRTQHIGNQE	0
962	NQEENKSKNR	0
963	QEENK <u>S</u> KNRN	0
1001	ESSDD <u>D</u> SDSE	0
1043	D F W Q M <u>I</u> F Q R K	0

1045	w o m i f o r K v K	0
1111	D S R T V Y Q Y Q Y	0
1142	v k Q k L <u>P</u> Q k n s	0
1149	к n	0
1153	EGNKH <u>H</u> KSTP	0
1168	R D G S Q <u>Q</u> T G I F	0
1212	TFEQY <u>Q</u> FL Y D	0
1226	TYPAQ <u>N</u> GQVK	0
1234	V K K N N <u>H</u> Q E D K	0
1239	HQEDK <u>I</u> EFDN	0
1240	Q E D K I <u>E</u> F D N E	0
1270	PEAKE <u>Q</u> AE G S	0
1282	TSGTE <u>G</u> PE HS	0
242	втк ь	-1
260	и итст<u>и</u>ие v н	-1
366	D S E I L Y N N H K	-1
392	EPQII <u>F</u> CRSE	-1
414	Q R S F H <u>N</u> F T L C	-1
496	D N S M H V K C R P	-1
505	PPRDR <u>N</u> GPHE	-1
528	R N E S H K N C D F	-1
534	исрек <u>ч</u> крьо	-1
612	EQQELVERDD	-1
613	QQELV <u>E</u> RDDE	-1
618	ERDDE <u>K</u> QLMN	-1
620	D D E K Q L M N V E	-1
654	EFQSI <u>P</u> RVFS	-1
716	EPRKY <u>I</u> A A Q G	-1
726	PRDET <u>V</u> DDFW	-1
727	RDETVDDFWR	-1
757	RNKCA <u>E</u> YWPS	-1
818	PDHGV <u>P</u> EDPH	-1
938	EPSPL <u>E</u> AEFQ	-1
965	enksk <u>n</u> Rn s n	-1
1000	Desenbras	-1
1004	D D D S D <u>S</u> E E P S	-1
1066	D Q E I C A Q Y W G	-1
1091	тркѕѕ <u>т</u> чт ь к	-1
1096	TYTLR <u>V</u> F E L R	-1
1101	V F E L R <u>H</u> S K R K	-1
1117	Q Y Q Y T <u>N</u> W S V E	-1

1169	D	Ģ		3	Q	Q	<u>T</u>	G	I	F	C
1288	P	E	Į	Ι	Ş	V	<u>N</u>	G	P	A	5
28	P	8	. 1	þ	Ť	G	Ŀ	T	Ţ	A	K
64	E	N	1	D	F	s	<u>e</u>	T	T	T	\$
85	P	D		5	L	D	<u>N</u>	A	s	A	F
147	P	G	1	Ε	R	s	T	A	s	T	F
671	R	K	. 1	P	F	N	<u>Q</u>	N	K	N	R
753	E	E	1	G	N	R	N	ĸ	C	A	E
787	C	F	, ,	D	Y	I	Ī	Q	K	L	N
925	P	¥	: 1	L	H	N	<u>M</u>	ĸ	K	R	D
945	E	F	• (Q	R	L	<u>P</u>	8	Y	R	5
950	₽	5	, .	Y	R	s	W	R	T	Q	H
964	В	E		N	ĸ	s	K	N	R	N	8
994	E	٤	;	E	H	D	<u>\$</u>	ø	E	3	Ş
1027	P	F	3	٧	M	I	A	A	Q	G	P
1131	E	E	>	K	E	L	I	S	M	I	Q
1207	P	G	;	M	v	s	I	F	E	Q	Y
138	P	G	j	8	N	A	I	8	D	٧	P
257	E	(•	G	N	N	T	C	T	N	N
298	P	3	>	G	v	Ê	K	F	Q	L	Н
483	P	5	3	Q	٧	W	N	M	Т	v	S
547	D	• 3	Č	т	F	K	A	Y	F	н	Ņ
647	E	•	3	R	L	F	Ŀ	A	E	F	Q
659	P	١ '	3.	ν	F	S	K	F	₽	I	K
939								E			
996	E	; ;	Ħ	D	S	D	E	5	s	D	ם
1266								A			
358	E	;]	P	E	Н	E	¥	K	C	ם	8
362								E			
717	P	,	R	ĸ	Y	I	A	A	Q	G	F
1076								G			
1147								E			
1245								ַ ב			
1280								E			